Saturday, April 4

Science is not neutral: The rubella vaccine and the attack on public health


This the second part of a two-part article. The first part can be viewed here.

Plotkin and the rubella vaccine

As Dr. Stanley Plotkin recently explained to the WSWS, the mid-century vaccinologist worked with severely limited tools: “At that time we had only two ways to make vaccines: attenuation of the agent or inactivation of the agent.” Plotkin chose attenuation—the Pasteurian principle of weakening a pathogen until it can stimulate immunity without causing disease. 

Dr. Stanley Plotkin at work in his laboratory at the Wistar Institute, where the RA 27/3 rubella strain was isolated, attenuated, and prepared for human trials in the mid-1960s. [Photo by Stanley Plotkin]

Plotkin executed this Pasteurian logic with mid-century precision but made one crucial departure from conventional practice: He chose to cultivate the rubella virus in human cells rather than animal substrates. Animal tissues—monkey kidneys, duck embryo cells—were notoriously prone to contamination with latent pathogens, including the cancer-associated SV40 virus that had contaminated early polio vaccines. 

There was a deeper scientific logic at work as well. Unlike most pathogens, rubella has no known animal reservoir—It exists exclusively in human populations and replicates most faithfully in human tissue. A virus with no animal host, Plotkin must have reasoned, should be attenuated in the cells it targets. Growing it through animal substrates risked producing a strain mismatched to the human immune system it needed to train. Human cells were not merely cleaner; for this pathogen, they were demonstrated to be scientifically correct. 

The essential substrate for Plotkin’s vaccine was a cell line known as WI-38. Developed in 1962 at the Wistar Institute by biologist Leonard Hayflick, WI-38 was derived from the lung tissue of a legally aborted fetus in Sweden. The woman who underwent the abortion—a mother who felt she could not manage another child—is known in historical accounts only as “Mrs. X.” Her name was never recorded in scientific literature, and she has declined, in the decades since, to be identified.

Hayflick’s cells were a breakthrough. Unlike the monkey tissues commonly used at the time, they were free of dangerous animal viruses, and they could divide reliably through approximately 50 generations in the laboratory before naturally reaching senescence—a phenomenon Hayflick himself had discovered and that now bears his name, the Hayflick limit.

Using the WI-38 cells, Plotkin isolated the rubella virus from the kidney of a fetus aborted during the epidemic. He designated the resulting viral strain RA 27/3—Rubella Abortus, the 27th specimen tested, the 3rd tissue explant—a naming convention that preserved in shorthand the precise conditions of the strain’s discovery.

To attenuate the virus, Plotkin grew it repeatedly in WI-38 cells while progressively lowering the incubation temperature—from 35 degrees Celsius down to 30. Each passage through these cooler, artificial conditions forced the virus to accumulate mutations favoring laboratory survival over replication in the human body. By the 25th passage, the strain had been sufficiently weakened: It could still stimulate the immune system, but it could no longer cause disease.

When it came time to test RA 27/3, Plotkin selected a setting rich in historical irony: St. Vincent’s Home for Children, a Philadelphia orphanage administered by Catholic nuns. The trial proceeded with the explicit written blessing of Archbishop John Joseph Krol. Decades later, it would be the Catholic Church’s own anti-abortion constituencies—along with broader right-wing anti-vaccine forces—who would attack the vaccine precisely because of its origins in fetal cell tissue, targeting a scientific legacy that the Archbishop had once endorsed.

The vaccine, however, ran immediately into regulatory resistance. Despite its demonstrated safety and immunogenicity, American regulators refused to approve RA 27/3 for a decade—a delay driven not by scientific evidence but by institutional prejudice against human cell substrates. The government’s Division of Biologics Standards, led by Roderick Murray, stubbornly favored vaccines grown in animal tissues, warning that human cell strains might harbor hypothetical cancer-causing agents—this from an agency that had authorized monkey kidney cells repeatedly shown to carry actual dangerous contaminants, including SV40.

While American regulators stalled, Plotkin’s vaccine was licensed and deployed across Europe, accumulating a decade of safety data. The impasse in the United States was finally broken by Dorothy Horstmann, a Yale virologist whose comparative field studies demonstrated conclusively that the animal-based rubella vaccines approved in the US failed to prevent reinfection at the rates Plotkin’s strain did. RA 27/3 produced higher and more durable antibody levels, better resistance to reinfection, and—critically—a stronger mucosal immune response in the nasopharynx, precisely where the virus first established itself. 

Horstmann’s data persuaded Maurice Hilleman, Merck’s chief virologist, to abandon his company’s duck-embryo formulation and adopt Plotkin’s strain. In 1979, the Food and Drug Administration (FDA) finally approved RA 27/3, making it the standard rubella vaccine in the United States—10 years after it had been in use in Europe.

Elimination of rubella

The introduction of routine rubella vaccination in the United States in 1969 produced an immediate and dramatic reduction in infections and congenital tragedies. The delivery mechanism that made this population-wide protection possible was the measles-mumps-rubella (MMR) vaccine, a combination formulation developed by Maurice Hilleman at Merck in 1971 that united measles, mumps and rubella immunization in a single shot. By 1979, Plotkin’s RA 27/3 strain had replaced earlier animal-substrate formulations as the rubella component of the MMR. It remains so today, in every MMR vaccine administered anywhere in the world.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *